Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference
Published: Mar 19, 2013
The Nanobiotix presentation is scheduled on Friday 5 April 2013 at 10:30 am ET in room 508 at the Millennium Hotel in New York, NY. Laurent Levy will provide an overview of the Company’s strategy, technology and pipeline including its NanoXray technology, which has been developed to enhance radiotherapy energy to destroy tumor cells while not causing additional damage to the healthy surrounding tissue. Following the presentation there will be a breakout session from 11:00am – 11:30am ET, in room 507.
The conference, which is co-hosted by BioCentury and Thomson Reuters, invites companies in key therapeutic areas to present a 25-minute company overview to leading portfolio managers, bankers and analysts. Nanobiotix is one of the few European Companies invited to present.
For more information about the conference, please visit: http://www.biocentury.com/conferences/futureleaders
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy and brachytherapy treatments and are applicable to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The company is based in Paris, France.
For more information, please visit www.nanobiotix.com
For more information, please contact:
+33 (0)1 40 26 07 55
and investors relations Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59
Media relations (Europe excl. France)
Melanie Toyne Sewell / Anastasios Koutsos / Donia Al Saffar
+44 (0) 207 457 2020